BioCytics has partnered with Eremid Genomic Services to advance their innovative cancer cell therapy using single-cell transcriptomics, enhancing personalized medicine.

Explore the innovative collaboration between UNC Charlotte and BioCytics to identify genomic features driving cancer growth and treatment responses.

BioCytics and LIDE Biotech have formed a strategic alliance to develop advanced screening platforms for cancer therapies. This partnership aims to revolutionize personalized medicine.

HUNTERSVILLE, N.C., Aug. 13, 2026 /PRNewswire/ -- BioCytics, Inc., and LIDE Biotech are proud to announce the formation of a strategic alliance to develop advanced screening platforms and companion diagnostics for immune-based cancer cell therapies. This collaboration combines BioCytics'...

HUNTERSVILLE, N.C., July 17, 2026 /PRNewswire/ -- BioCytics, Inc., in partnership with Carolina BioOncology Institute, PLLC, and UNC Charlotte are proud to announce the launch of an exciting research initiative aimed at identifying relevant genomic features that contribute to cancer cell...

BioCytics announces a key milestone with the FDA INTERACT meeting, setting the stage for its cell therapy platform aimed at combating solid tumors.

BioCytics has received a $100,000 G-Rex grant from ScaleReady to advance its innovative cell-based therapy for cancer treatment. This funding supports the development of immune cell manufacturing processes.